<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04811651</url>
  </required_header>
  <id_info>
    <org_study_id>k（2019）46</org_study_id>
    <nct_id>NCT04811651</nct_id>
  </id_info>
  <brief_title>Umbilical Cord-derived Mesenchymal Stem Cells for Ischemic Stroke</brief_title>
  <acronym>UMSIS</acronym>
  <official_title>Umbilical Cord-derived Mesenchymal Stem Cells for Ischemic Stroke (UMSIS): a Prospective, Double-blinded, Randomized Controlled, Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>General Hospital of Shenyang Military Region</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>General Hospital of Shenyang Military Region</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a doble blind, placebo controlled clinical trial to assess safety and efficacy of&#xD;
      intravenous administration of Umbilical cord-derived Mesenchymal Stem cells in patients with&#xD;
      ischemic stroke within 6 months of onset.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 15, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Two different treatment groups; intravenous umbilical cord-derived mesenchymal stem cells or intravenous placebo solution</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Treatment and placebo solutions have identical appearance. Protocols will be designed to ensure that the physician evaluating patient safety and efficacy outcome as well as laboratory analysis, will not have access to the randomisation codes.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of modified Rankin Scale (mRS) 0-2</measure>
    <time_frame>90 Days</time_frame>
    <description>the minimum and maximum values of mRS are 0 and 6, respectively; higher mRS mean a worse outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of modified Rankin Scale (mRS) 0-2</measure>
    <time_frame>180，360 Days</time_frame>
    <description>the minimum and maximum values of mRS are 0 and 6, respectively; higher mRS mean a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in Fugl-Meyer scale</measure>
    <time_frame>90days；180days；360days</time_frame>
    <description>Fugl-Meyer Assessment Scale ranges from 0 to 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in Purdue hand function test</measure>
    <time_frame>90days；180days；360days</time_frame>
    <description>The changes of fine motor function were evaluated by Purdue hand function test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in box and block test</measure>
    <time_frame>90days；180days；360days</time_frame>
    <description>The changes of fine motor function were evaluated by box and block test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of modified Rankin Scale (mRS) 0-1</measure>
    <time_frame>90days；180days；360days</time_frame>
    <description>the minimum and maximum values of mRS are 0 and 6, respectively; higher mRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in the national institutes of health stroke scale (NIHSS)</measure>
    <time_frame>90days；180days；360days</time_frame>
    <description>NIHSS ranges from 0-42, and high NIHSS means bad outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in Mini-mental State Examination (MMSE) score</measure>
    <time_frame>90days；180days；360days</time_frame>
    <description>MMSE score ranges from 0 to 30.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in Montreal Cognitive Assessment (MoCA) score</measure>
    <time_frame>90days；180days；360days</time_frame>
    <description>MOCA score ranges from 0 to 30.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The changes of head images</measure>
    <time_frame>90days；180days；360days</time_frame>
    <description>head images included flair, DTI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in some serum biomarkers</measure>
    <time_frame>90days；180days；360days</time_frame>
    <description>serum biomarkers included CPEC, VEGF, BDNF, MMP-9</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>360days</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intravenous umbilical cord derived mesenchymal stem cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>intravenous placebo solution with the same appearance as the treatment group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Umbilical Cord-derived Mesenchymal Stem Cells</intervention_name>
    <description>umbilical cord derived mesenchymal stem cells were intravenously injected in a single dose of one hundred million.</description>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>intravenous placebo solution with the same appearance as the treatment group.</description>
    <arm_group_label>Placebo Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age: 18-80 years old;&#xD;
&#xD;
          2. Patients with anterior circulation cerebral infarction;&#xD;
&#xD;
          3. NIHSS: 6-25, and the limb movement score is at least 2 points;&#xD;
&#xD;
          4. Hemoglobin &gt; 115g / L, platelet &gt; 100 × 109 / L, leukocyte &gt; 3 × 109 / L;&#xD;
&#xD;
          5. the time from onset to treatment: group A（6-24 hours）、group B（1-3 days）、gourp C（4-7&#xD;
             days）、group D（1-4 weeks）、group E（1-6 months）;&#xD;
&#xD;
          6. The patient or the legal representative of the patient can and is willing to sign the&#xD;
             informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who need or expect decompressive craniectomy;&#xD;
&#xD;
          2. Patients who need or are expected to receive endovascular treatment ;&#xD;
&#xD;
          3. Patients receiving intravenous thrombolysis;&#xD;
&#xD;
          4. Disturbance of consciousness；&#xD;
&#xD;
          5. Pregnant women or women of childbearing age who have not taken effective contraceptive&#xD;
             measures;&#xD;
&#xD;
          6. Intracranial hemorrhagic diseases: cerebral hemorrhage, subarachnoid hemorrhage, etc;&#xD;
&#xD;
          7. Posterior circulation cerebral infarction;&#xD;
&#xD;
          8. Tumor patients;&#xD;
&#xD;
          9. Epilepsy patients;&#xD;
&#xD;
         10. Severe neurological deficit caused by stroke (MRS = 5);&#xD;
&#xD;
         11. Previous diseases with obvious functional impairment, such as Parkinson's disease,&#xD;
             motor neuron disease, moderate Alzheimer's disease, osteoarthritis, etc;&#xD;
&#xD;
         12. Patients with history of coagulation disorders, systemic bleeding tendency and&#xD;
             thrombocytopenia (&lt; 100000 / mm3);&#xD;
&#xD;
         13. Chronic liver disease, liver and kidney dysfunction, elevated ALT or ast (2 times&#xD;
             higher than the upper limit of normal value), elevated serum creatinine (1.5 times&#xD;
             higher than the upper limit of normal value) or dependent on renal dialysis;&#xD;
&#xD;
         14. Patients with moderate to severe mental illness obviously interfere with treatment&#xD;
             compliance;&#xD;
&#xD;
         15. Patients with high blood pressure (systolic blood pressure &gt; 180mmhg) or low blood&#xD;
             pressure (systolic blood pressure &lt; 90mmHg);&#xD;
&#xD;
         16. The expected survival time is less than one year;&#xD;
&#xD;
         17. Those who have conducted other trials within 3 months;&#xD;
&#xD;
         18. Other circumstances considered unsuitable by the researcher.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chen Hui-Sheng, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>General Hospital of Shenyang Military Region</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chen Hui-Sheng, Doctor</last_name>
    <phone>86-24-28897511</phone>
    <phone_ext>024-28897512</phone_ext>
    <email>chszh@aliyun.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wang Xin-Hong, Doctor</last_name>
    <phone>86-15309885658</phone>
    <email>450341972@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Neurology, General Hospital of Northern Theater Command</name>
      <address>
        <city>Shenyang</city>
        <zip>110016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hui-Sheng Chen, Ph.D.</last_name>
      <phone>+86 13352452086</phone>
      <email>chszh@aliyun.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 15, 2021</study_first_submitted>
  <study_first_submitted_qc>March 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2021</study_first_posted>
  <last_update_submitted>March 19, 2021</last_update_submitted>
  <last_update_submitted_qc>March 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>General Hospital of Shenyang Military Region</investigator_affiliation>
    <investigator_full_name>Hui-Sheng Chen</investigator_full_name>
    <investigator_title>Director of neurology department</investigator_title>
  </responsible_party>
  <keyword>Ischemic Stroke</keyword>
  <keyword>Stem Cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

